

Immunological Assessment Pre and Post Transplant

Indira Guleria, Ph.D D (ABHI), CABP (H)
Director, HLA Laboratory
Department of Pathology
Beth Israel Deaconess Medical Center (BIDMC)
Associate Professor of Pathology, Harvard Medical School

Indira Guleria, PhD. D(ABHI)*



- Graduate studies in Immunology at National Institute of Immunology, New Delhi, India
- Post-doctoral (HHMI) Fellowship @Albert Einstein College of Medicine, Bronx, NY
- Director HLA Laboratory @BIDMC
- Associate Professor of Pathology@ HMS
 - Clinical focus: Solid And Stem Cell transplantation
 - Research focus: Mechanisms of Transplant Tolerance

* Diplomate (American Board of Histocompatibility and Immunogenetics)

Disclosures

- I have no financial disclosures

Objectives

- Use clinical cases to:
 - highlight differences between solid phase and cell based assays
 - determine the strength of anti-HLA antibodies
 - understand the concept of auto-antibodies
 - learn about possible interfering factors (immunosuppressive agents) that can affect HLA lab assays



Cell (Donor) based

Solid phase Bead based assays

T cells express Class I only

B cells express Class II (&I)

T ~ Class I
B ~ Class II



Only HLA IgG

Cell based Assays (Ag-Ab) differ from Single antigen Bead Assays (Ab)

CASE-1: RR

Patient who has a positive cross match (B cell FLOW Xm) with negative result for anti donor specific antibody (Antibody Screening for HLA antigens by Single antigen bead testing)

In the absence of any single antigen bead reactivity in an assay that detects antibodies to HLA class I or class II antigens

- what could be the possible reasons for this positivity?

- is this reactivity relevant to clinical outcomes post transplant (likelihood)?

Crossmatch = Xm

Summary of results

Patient Antigens: A1 A24 B27 B44 Cw7 Cw10 DR15 DR51 DQ6

Donor Antigens: A2 A33 B35 B7 Cw7 DR11 DR52 DQ6

T cell CDC Xm Negative

B cell CDC Xm Negative

T Flow Xm negative

B Flow Xm positive

All testing is valid

**Antibody screening: No donor specific anti-HLA antibodies
(DSA) detected by single antigen bead assay**

Two different assays

Cell based assays (crossmatch assays – B cell Flow Xm in this case) will pick up **Non-HLA antibodies** in addition to HLA antibodies

Other Possible Reasons for Positive B Cell Flow Xm

And/Or


Background due to B cells expressing

- Fc receptors
- Surface IgG
- Antibodies can non-specifically bind to these and resulting positivity is Not a contra-indication to transplant

Function	Activating					Inhibitory
Structure	Immunoglobulin domain Common γ -chain ITAM					ITAM
Cell membrane	GPI anchor					ITAM
Name	Fc γ RI	Fc γ RIIA	Fc γ RIIC	Fc γ RIIA	Fc γ RIIB	Fc γ RIIB
Expression	Lymphoid Not expressed	Not expressed	NK cell	NK cell	Not expressed	B cell and plasma cell
Myeloid	Monocyte, DC and macrophage	Monocyte, DC, platelet and macrophage	Not expressed	Monocyte, DC and macrophage	Not expressed	Monocyte, DC and macrophage
Granulocyte	Neutrophil and eosinophil	Neutrophil	Not expressed	Not expressed	Neutrophil, mast cell and eosinophil	Neutrophil, basophil and mast cell
IgG binding affinity	IgG1>>>IgG2, IgG3 and IgG4	IgG1 and IgG3>> IgG2>IgG4	IgG1>IgG3>> IgG4>IgG2	IgG1>>IgG2 and IgG3 >IgG4	IgG1 and IgG3>> IgG2 and IgG4	IgG1>IgG3>> IgG4>IgG2

Fc Receptors

Smith and Clatworth Nat Rev Immuno 2010



Surface Immunoglobulins

Post-Transplant Monitoring

Antibody Testing using single antigen beads

- Diagnose AMR
 - Determine management of AMR by guiding immunosuppression
 - In patients that are at immunological risk (e.g. sensitized, prior episode of Antibody Mediated Rejection) more closely monitoring
 - Prognostic information: Persistent or high strength antibodies may predict poor graft outcomes
- **Objective: To determine which Ab tests should be ordered in the setting of AMR and how these results should be followed with treatment**

Need for a way for Quantitation

Post-Transplant Monitoring- Case -2-LK

HLA Typing

Patient Antigens: A3 A30 B35 B45 BW6 Cw4 DR11

Donor Antigens: A2 B44 B70 Bw4 Bw6 Cw5 Cw10 **DQ4 DQ9** DR7 DR18 DR52

Candidate Antibody Screening (before and at the time of transplant)

Class I: HLA -A66, -A68, -A69 **No Class I** donor specific anti-HLA antibodies

Class II: HLA-DQ2, -DQ5, -DR12 **No Class II** donor specific anti-HLA antibodies

Crossmatch (at the time of transplant)

T CELL CDC Xm Negative

B CELL CDC Xm Negative

Antibody Screening - Post-Transplant

HLA Typing

Patient Antigens: A3 A30 B35 B45 BW6 CW4 DR11

Donor Antigens: A2 B44 B70 Bw4 Bw6 Cw5 Cw10 DQ4 DQ9 DR18 DR52 DR7

Antibodies – post-transplant

Class I: HLA-**A2**, -A25, -A26, -A66, -A68, -A69 (*de novo* development of antibody to one of the mismatched HLA-A antigen, A2, Pre-transplant no class I antibody but A2 mismatch was there so potential to develop antibodies did exist, with immunosuppression you can minimize but not erase this risk)


Class II: HLA - **DQ4**

**Donor specific Antibodies: Anti-HLA-A2 (de novo development)
and Anti-DQ4 (de novo development)**

De novo antibodies carry worse prognosis if persistent (hence close **monitoring**)

Titers - Post Transplant monitoring tool - (plasmapheresis/rituximab)

Strong Antibody May Not Dilute in Titer



Titers are performed to measure strength of the antibody
Strong Antibodies DO NOT Dilute out – Antibody 2 in this case

Anti-A2 (Blue bars) the *de novo* antibody was diluting out – thus intervention will be relatively manageable – but antibodies had to be monitored after each intervention

Conclusion = Ab monitoring used to guide treatment of AMR; Class II antibodies are relatively difficult to remove

Case-3: Patient EC – Highly sensitized patient - Correlation Screening vs Xm

Single Antigen Class I Serum Screening Results

B81	B39
B48	B35
B60	B72
B67	B62
B61	B76
B50	B55
B18	B82
B27	B54
B41	B75
B8	B78
B45	B56
B42	B64
B71	B65
B7	B73
B75	B46
B61	

Bw6- public epitope present on
all the B antigens depicted on the left columns)

(All These Are “Bw6”)

cPRA = 97%
Highly sensitized)

Other non-Bw6 antibodies present

A66, A68, A34, B27, B51, B52, B13, B47, B59, B63, B38

Patient EC Class I Antibody Profile


3000
Std cutoff

1000
low cutoff

22,000

Antibodies did not dilute out
when titers were performed

Bw6
Public Epitope



Patient EC - Correlation Screening vs Xm

- cPRA by Single Antigen = 97% - **Screening assay**
- 41/47 T cell Cytotoxic **Crossmatches** (T CDC) against deceased donors were positive = 87%

Good Correlation between screening
and Xm result

Case 4: Patient AB

Correlation Screening vs Xm

Single Antigen Class I Serum Screening Results

A43
A11
A26
A68
B8
B13
B45
B76
B13
B44
B82

cPRA = 62%

Even though high enough PRA



Only 1/31 T cell cytotoxic
crossmatches (T CDC Xm) against
deceased donors were positive =
3%

Lack of Correlation between screening
and Xm result

Patient AB Class I profile compared to that of Patient EC


3000
Std cutoff

1000
low cutoff



Patient AB – Lack of Correlation between screening and Xm result

- Even though the cPRA is high, class I antibodies are Not strong enough to cause a positive **cytotoxic crossmatch**



Complement binding antibody:
Antibody strong antibody/more
molar amount
~ complement binding

Copyright © 2003, Elsevier Science (USA). All Rights Reserved.

Case-5- EM

Auto-antibodies

0/6 antigen (HLA-A, -B, -DR) match but no donor specific antibody to mismatched antigens

CDC T and CDC B cell **Allo XM**: **Both** positive

Flow T and Flow B cell Allo Xm: Negative

What does this tell us about characteristic of this antibody?

False positive (technical error)

Or Positive due to auto-antibodies, clinically irrelevant antibodies

Other clinical history: Lupus

Is it safe to proceed? What additional information is needed for **full** immunological assessment?

CDC Crossmatch Detects IgM Antibodies

Dithiothreitol (DTT) Treatment

DTT reduces disulfide bonds in IgM antibodies.

Original CDC crossmatch was positive and became negative after DTT treatment:

- **DTT CDC T-cell XM:** Negative
- **DTT CDC B-cell XM:** Negative

This suggests the reactivity was due to IgM antibodies.

Role of Autologous Crossmatch

Autoantibodies are commonly IgM.

To determine whether the reactivity is due to autoantibodies, an autologous crossmatch can be performed using recipient lymphocytes instead of donor lymphocytes.

Autologous XM was positive and became negative after DTT treatment, supporting IgM autoantibody-mediated reactivity.

Clinical Interpretation

The findings support IgM autoantibody-mediated reactivity:

- Positive auto-crossmatch
- Loss of reactivity after DTT treatment

IgM autoantibodies are generally considered not clinically significant in transplantation.

Important Consideration: Rare IgM alloantibodies may have clinical significance and should be interpreted in the appropriate clinical context.

Case 6 – BC

Non-specifically Unexpected Positive Crossmatch OR Invalid Crossmatch results

Autologous Crossmatch: Example of Rituximab Interference

Patient received rituximab (anti-CD20 therapy)

Autologous Flow Crossmatch

T-cell XM: Negative (valid)

B-cell XM: Invalid — recipient B cells depleted, preventing assessment

Allogeneic B-cell Flow Crossmatch

May be falsely positive due to rituximab binding to donor CD20-positive B cells

Positive result may occur in the absence of DSA

Clinical Interpretation:

- A positive B-cell flow crossmatch after rituximab therapy may reflect drug interference rather than donor-specific HLA antibodies.
- Autologous crossmatch results can help identify treatment-related effects and aid interpretation.

Question 1

Donor Antigens: A2 B44 B70 Bw4 Bw6 Cw5 Cw10 **DQ4 DQ9** DR18 DR52 DR7

Patient/candidate antibody profile:

Class I: HLA -A66, -A68, -A69 **No Class I** donor specific anti-HLA antibodies

Class II: HLA-DQ2, -**DQ4** -DQ7, -DQ8, -**DQ9**

Patient has Class II DSA : anti-DQ4 and -DQ9 antibodies

Circle the right answer

- a) Class II DSA can result in a positive T cell crossmatch
- b) Class II DSA can result in a positive B cell crossmatch
- c) Crossmatch results due to Class II DSA's will always be negative
- d) Class II DSA can result in both T and B cell positive crossmatches

Question - 2

A living donor transplant candidate has the following assay results

Positive T and B cell CDC Xm, a Negative Flow Xm T and B cell results

No DSA (0% PRA) by antibody Screening for HLA antigens by Single antigen Luminex bead testing

What will you do next?

- a) Perform DTT treatment to determine if the antibodies are IgM isotype and determine if a negative Xm result is obtained post treatment with reducing agent DTT
- b) Perform auto-crossmatches to determine the contribution of autoantibodies to these positive crossmatches
- c) Enquire about autoimmune disease history if any on the patient
- d) All of the above
- e) None of the above

Summary

CDC Xm picks up both IgM and IgG, Flow Xm and single antigen bead assay picks up IgG

Cell based assays pick up non-HLA antibodies in addition to HLA antibodies

Strength of antibody can be tested by performing titers of the sera

Lack of correlation between antibody screening and crossmatch could be a function of strength (and isotype) of antibody

Crossmatch and antibody screening assays are complementary, not interchangeable. Discordance between assays requires evaluation of antibody specificity, isotype, strength, and clinical context before determining immunologic risk.